ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BioCryst Wins Ebola Contract

by Lisa M. Jarvis
April 6, 2015 | APPEARED IN VOLUME 93, ISSUE 14

BioCryst Pharmaceuticals has won a $12 million, 18-month contract from the Department of Health & Human Services to support the development of the potential Ebola treatment BCX4430. The funds will enable the Durham, N.C.-based biotech firm to prepare for large-scale manufacturing of the antiviral, which is currently in Phase I studies to establish its safety. BCX4430 is the first small molecule for Ebola to receive funding from HHS. If extended through August 2017, BioCryst’s contract could be worth $35 million. Separately, an Ebola vaccine being developed by NewLink Genetics and Merck & Co. is safe and prompts an immune response, according to a clinical trial conducted by the National Institutes of Health.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment